Phase 2 study of iodine-131 tositumomab plus chemotherapy in patients with previously untreated mantle-cell lymphoma Journal Article
| Authors: | Zelenetz, A. D.; Popplewell, L. L.; Noy, A.; Horner, T. J.; Lin, T. S.; Donnelly, G.; Sgouros, G.; Rijo, I.; Divgi, C. R. |
| Article Title: | Phase 2 study of iodine-131 tositumomab plus chemotherapy in patients with previously untreated mantle-cell lymphoma |
| Abstract: | Background: Mantle-cell lymphoma (MCL) is sensitive to radiotherapy, and the CD20 antigen is relatively highly expressed in MCL. Therefore, radioimmunotherapy using radiolabeled anti-CD20 monoclonal antibodies has the potential to treat MCL. The objective of this study was to investigate the efficacy, pharmacokinetics, and safety of tositumomab (TST) and iodine-131 tositumomab (I-131 TST) followed by 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with previously untreated MCL (ClinicalTrials.gov NCT00022945). Patients and Methods: In this phase 2 open-label study, patients received dosimetric (day 0: 450 mg TST, then 35 mg I-131 TST [5 mCi]) and therapeutic (between days 7 and 14: 450 mg TST, then an individualized dose of I-131 TST [65-75 cGy]) TST/I-131 TST, with CHOP treatment commencing approximately 13 weeks after the therapeutic dose. The primary end point was the MCL response rate to treatment; secondary end points included confirmed complete response rate and total body residence time. Results: Twenty-six patients were enrolled, and 25 were included in the intent-to-treat population. The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%. The median progression free-survival was 27.6 months. The median total body residence time was 94.5 hours. No new or unexpected safety signals were identified. Conclusion: Patients with previously untreated MCL who received radioimmunotherapy with TST/I-131 TST followed by CHOP had a high response rate and a long duration of response, indicating that radioimmunotherapy is a therapeutic option in this patient population. © 2019 This study demonstrated that the radiolabeled anti-CD20 monoclonal antibody therapy tositumomab and iodine-131 tositumomab followed by chemotherapy is a potential treatment for mantle-cell lymphoma. Fourteen of 25 patients with previously untreated mantle-cell lymphoma who received this treatment combination experienced complete response (CR), with a median CR duration of 31.8 months. No unexpected adverse events were observed. © 2019 |
| Keywords: | monoclonal antibody; radioimmunotherapy; chop; anti-cd20 |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 20 |
| Issue: | 11 |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-11-01 |
| Start Page: | 749 |
| End Page: | 756.e1 |
| Language: | English |
| DOI: | 10.1016/j.clml.2019.04.010 |
| PUBMED: | 32800518 |
| PROVIDER: | scopus |
| PMCID: | PMC10629362 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 December 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work